Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer

Background: Alectinib, a highly selective inhibitor of ALK, is currently used in the first-line setting of untreated advanced ALK-positive NSCLC and in the second-line setting of crizotinib-resistant ALK-positive NSCLC. Despite promising efficacy and tolerability in the treatment of advanced ALK-pos...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yan, Ren, Siying, Wang, Ruoyao, Han, Wei, Xiao, Peng, Wang, Li, Yu, Fenglei, Liu, Wenliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299059/
https://www.ncbi.nlm.nih.gov/pubmed/35873553
http://dx.doi.org/10.3389/fphar.2022.816683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299059/
https://www.ncbi.nlm.nih.gov/pubmed/35873553
http://dx.doi.org/10.3389/fphar.2022.816683

Ejemplares similares